Catalyst Wire Dossier Catalyst Wire Dossier

TVB-2640

· Sagimet Biosciences
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for TVB-2640, covering 2017-08-14 to 2026-02-24. Get the full timeline:

Most recent: Clinical Trial Update: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer [Phase 2]

See pricing